DaVita (DVA) traded lower Tuesday, May 5, 2026, with the move aligning with heightened focus on the company’s imminent first-quarter earnings report (expected after the close). With the print approaching, trading appears driven by positioning and sensitivity to near-term operating pressures that have been flagged across the dialysis space: treatment-volume softness linked to elevated mortality and cost inflation in patient care.

The key near-term debate is whether U.S. dialysis treatment volumes stabilize fast enough to offset ongoing cost pressures. Recent earnings-call commentary and previews have highlighted treatment-volume headwinds (including elevated mortality), rising patient care costs, and lingering operational drags such as cyber-related losses. Investors are also tracking payer/reimbursement friction, including headwinds tied to the expiration of enhanced premium tax credits and its effect on revenue per treatment dynamics into 2026.

The market’s reaction is likely to hinge on (1) U.S. treatment-volume trends and any update to full-year volume assumptions, (2) patient care cost growth relative to management’s cost outlook, and (3) whether full-year 2026 adjusted profit and cash-flow targets are reaffirmed without additional qualifiers. Any deviation in expected quarterly cadence (for example, whether Q1 contributes less than anticipated to full-year operating income) could amplify the move given the stock’s sensitivity to small changes in utilization and cost per treatment.